February 1, 2021
Government Operations Results for December 2020
For the period of April to December 2020, the GOJ reported Total Revenues & Grants of $398.26 billion, $378.2 million more than the Government’s projection. This represented a decrease of approximately 15.1% relative to the $469.16 billion recorded for the corresponding period in 2019. ‘Non-tax Revenue’ and ‘Grants’ outperformed projections during the review period. ‘Non-tax Revenue’ amounted to $47.77 billion, $594.7 million more than budgeted. ‘Grants’ amounted to $3.97 billion during the review period and outperformed the budget by $528.1 million. ‘Tax Revenue’ of $346.49 billion was reported, $744.6 million less than budgeted. Notably, no budgeted amount was booked for ‘Bauxite Levy’. ‘Capital Revenue’ closed the period with a provisional amount of $22.10 million, corresponding with the budgeted amount.
Total Expenditure for the period April to December 2020 amounted to $468.51 billion, $3.61 billion less than the budgeted amount of $472.12 billion. Recurrent expenditure which totalled $432.08 billion, accounted for 92.22% of overall expenditures. Of the recurrent expenditure categories for the review period, the only category above the budgeted amount was ‘Interest’. ‘Interest’ totalled $87.79 billion, 1.7% above the budgeted amount of $86.32 billion. Relative to projections, ‘Wages and Salaries’ amounted to $155.74 billion and was $63.4 million less than budgeted while ‘Programmes’ totalled $177.49 billion, 1.4% less than budgeted. Additionally, ‘Employee Contribution’ totalled $11.07 billion, 3.0% less than the budgeted amount of $11.41 billion.
The ‘Fiscal Deficit’ was $70.25 billion, relative to a ‘Projected Deficit’ of $74.24 billion. Additionally, the ‘Primary Surplus Balance’ for the period amounted to $17.53 billion, relative to the budgeted primary surplus of $12.08 million.
Analyst Certification –The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation (s) or view (s) expressed by that research analyst in this research report.
Company Disclosure –The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.